NEW

DRUG

CONCEPTS

DEVELOPING A HEALTHIER FUTURE

“ENDECE is dedicated to the discovery and development of treatments that stop disease progression, restore function, and improve quality of life.”

James Yarger, Ph.D.

President

LATEST NEWS

ENDECE is preparing to take NDC-1308 (MC1) into clinical studies as a potential treatment for SARS-CoV-2, which has caused the current COVID-19 pandemic. NDC-1308 (MC1) has the potential to reduce lung inflammation by upregulating key genes that produce active Lipoprotein Lipase (LPL) by targeting macrophages within the lungs.

ANTI-INFLAMMATORY and REMYELINATION

ANTI-INFLAMMATORY

ENDECE developed NDC-1308 (MC1), a potential treatment for SARS-CoV-2, which has caused the current COVID-19 pandemic. NDC-1308 (MC1) has the potential to reduce chronic lung inflammation.

REMYELINATION

NDC-1308 (MC2) directly up-regulates key genes within Oligodendrocyte Progenitor Cells (OPCs) of the Central Nervous System (CNS), inducing OPC differentiation to mature, myelinating Oligodendrocytes.